Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - LUMOS PHARMA, INC. | nlnk-20170228x8kxex991.htm |
| 8-K - 8-K - LUMOS PHARMA, INC. | a20170228-8k.htm |
NewLink Genetics Corporation
Nasdaq: NLNK
February 28, 2017
Fourth Quarter and Year-End 2016 Financial Results
Agenda
2
Introduction
Jack Henneman, Executive Vice President & CFO
2017 Ongoing Priorities
Charles J. Link, Jr., M.D., Chairman, CEO & CSO
Clinical Updates / Anticipated News Flow
Nicholas N. Vahanian, M.D., President & CMO
Fourth Quarter and Year-End 2016 Financial Results
Mr. Henneman
Cautionary Note Regarding Forward-Looking Statements
This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks
and uncertainties. All statements, other than statements of historical facts, contained in this presentation
are forward-looking statements, within the meaning of The Private Securities Litigation Reform Act of 1995.
The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "target," "potential," "will,"
"could," "should," "seek" or the negative of these terms or other similar expressions are intended to identify
forward-looking statements, although not all forward-looking statements contain these identifying words.
These forward-looking statements include any statements other than statements of historical fact. Actual
results or events could differ materially from the plans, intentions and expectations disclosed in the forward-
looking statements that NewLink Genetics makes due to a number of important factors, including those
risks discussed in "Risk Factors" and elsewhere in NewLink Genetics' Annual Report on Form 10-K for the
year ended December 31, 2015 and other reports filed with the U.S. Securities and Exchange
Commission (SEC). The forward-looking statements in this presentation represent NewLink'
Genetics' views as of the date of this presentation. NewLink Genetics anticipates that subsequent events
and developments will cause its views to change. However, while it may elect to update these forward-
looking statements at some point in the future, it specifically disclaims any obligation to do so. You should,
therefore, not rely on these forward-looking statements as representing NewLink Genetics' views as of any
date subsequent to the date of this presentation.
3
4
NewLink Genetics – 2016 Takeaways
The IDO pathway is central to immune escape in many types of cancers
The IDO pathway is becoming increasingly validated as an immuno-oncology target
Two product candidates that target the IDO pathway, with distinct mechanisms of action
GDC-0919; Targets the enzyme directly (partnered with Genentech/Roche)
Indoximod; Inhibits effects of IDO pathway by supplying a “tryptophan-sufficiency” signal
Proven track record in both in-licensing and out-licensing
Strong balance sheet to advance current preclinical and clinical programs
IDO Pathway Inhibitor Clinical Development
5
AGENT INDICATION REGIMEN PHASE 1 PHASE 2 PHASE 3
Indoximod
Advanced Melanoma
Indoximod + PD-1 inhibitors or
ipilimumab
Metastatic Pancreatic Cancer
Indoximod + gemcitabine
and nab-paclitaxel
Metastatic Breast Cancer Indoximod + taxane
Malignant Brain Tumors Indoximod + temozolomide
Castrate Resistant Prostate Cancer
(CRPC)
Indoximod + sipuleucel-T
Newly Diagnosed Acute Myeloid
Leukemia (AML)
Indoximod + standard of care
Advanced Non-Small Cell Lung
Cancer (NSCLC)
Indoximod + tergenpumatucel-L +
chemotherapy
GDC-0919*
Solid Tumors GDC-0919 + atezolizumab (PDL-1)
Solid Tumors GDC-0919
*Partnered with Genentech/Roche
ENROLLING
ENROLLING
ENROLLING
ENROLLING
ENROLLING
ENROLLED
ENROLLED
ENROLLED
ENROLLED
Fourth Quarter and Year-End 2016 Financial Results
YE Cash and Equivalents $131.5 million
Debt ~$0.5 million
YE 2017 Cash (Projected) ~$75 million
Quarterly Negative Cash-Flow ~$13 million
Shares Outstanding 29.2 million
Market Capitalization $435 million*
Headcount 122
6
*As of February 21, 2017
Major 2017 YE Cash Projection Assumptions: This excludes potential payments from partners, the proceeds from any
offerings, and any costs associated with any strategic transactions.
7
Q & A